M
Mission Bio
The equipment for molecular biology
About Mission Bio
Mission Bio is a biotechnology startup that operates in the field of cancer research. The company provides a unique technology platform, Tapestri, which allows researchers to analyze the genetic makeup of individual cells in a sample. This single-cell resolution can help identify rare genetic variations and provide a more detailed understanding of a patient's cancer.
The company's primary clients are cancer researchers and pharmaceutical companies developing cell and gene therapies. By providing a more detailed view of the genetic landscape of a tumor, Mission Bio's technology can help these companies develop more effective treatments and avoid late-stage failures in clinical trials.
Mission Bio operates in the rapidly growing market for genomics and precision medicine. The company's business model is based on selling its Tapestri platform and related services to researchers and pharmaceutical companies. The platform can measure multiple attributes within one assay, providing a comprehensive view of the genetic variations in a tumor. This can help researchers identify potential biomarkers that can be used to stratify patients, predict relapse, and signal resistance to treatment.
In summary, Mission Bio is a biotech startup that provides a unique technology platform for cancer research. The company's Tapestri platform allows researchers to analyze the genetic makeup of individual cells, providing a more detailed understanding of a patient's cancer and helping to develop more effective treatments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- South San Francisco, United States
- Employees
- 84
- Open positions
- None listed
- Dealroom signal
- 62.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Precision Medicine, Synthetic Biology, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Aug 2025 | $0 | — | Ally Bridge Group | ↗ |
| DEBTDebt | Jan 2022 | $40M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Mission Bio is 16K monthly website visits, up 0% over the last three months. Mission Bio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Keiretsu Forum
Fusion Fund
The Angels' Forum
Life Science Angels
National Human Genome Research Institute
Series A9 investors entered at this stage
Tech Coast Angels
Signatures Capital
Seabed VC
Mayfield
Mighty Capital
Foothill Ventures
Tapestri
Cota Capital
Agilent
Series B and later4 investors entered at this stage
Novo Seeds
Novo Holdings- SCSoleus Capital
Ally Bridge Group
Other known investors2 additional known investors
Sand Hill Angels
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mission Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mission Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.